The role of interleukin-1 in general pathology
Open accessThe DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
Abstract
Interleukin-1, an inflammatory cytokine, is considered to have diverse physiological functions and pathological significances and play an important role in health and disease. In this decade, interleukin-1 family members have been expanding and evidence is accumulating that highlights the importance of interleukin-1 in linking innate immunity with a broad spectrum of diseases beyond inflammatory diseases. In this review, we look back on the definition of "inflammation" in traditional general pathology and discuss new insights into interleukin-1 in view of its history and the molecular bases of diseases, as well as current progress in therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · cited 2×
“IL-1β generated in a tissue with a tumor microenvironment dominated by TAMs promotes tumor growth and metastasis in breast cancer [122, 125] .”
BackgroundAntiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · cited 2×
“The inhibition of IL-1 with anakinra improved glycemia and the pancreatic β-cell function and reduced systemic inflammation [205].”
BackgroundInflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199 · cited 1×
“The classical signs of inflammation are considered to be related to cells and tissues responding to pathological cell injury caused by internal stimuli, including damage-associated products and metabolites, and external stimuli, including bacteria and viruses [3] [4] [5] [6] .”
BackgroundPattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death
Shi, J., Zhao, Y., Wang, K., Shi, X., Wang, Y., Huang, H., Zhuang, Y., Cai, T., Wang, F., & Shao, F. (2015) · Nature · doi:10.1038/nature15514 · Cited by 6,659 · cited 1×
“This cell death is mediated by the caspase-1-dependent cleavage of gasdermin-D (GSDMD) [67] [68] [69] .”
BackgroundOrigin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618 · cited 1×
“In addition to several forms of inflammation including classical inflammation, homeostatic inflammation, a distinct nomenclature for low-grade inflammation, such as para-inflammation (an adaptive response against stress or malfunction) and meta-inflammation (metabolically triggered inflammation), has been proposed [17…”
BackgroundMartinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066 · cited 1×
“IL-1β is produced as a 269-AA precursor protein and processed by caspase-1, which is also known as IL-1β-converting enzyme (ICE), activated in inflammasomes, to the C-terminal 153 AA as mature IL-1β [11, 12, 34, 44].”
BackgroundInflammatory Mechanisms in Obesity
Gregor, M. F., & Hotamisligil, G. S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101322 · Cited by 3,754 · cited 1×
“The classical signs of inflammation are considered to be related to cells and tissues responding to pathological cell injury caused by internal stimuli, including damage-associated products and metabolites, and external stimuli, including bacteria and viruses [3] [4] [5] [6] .”
BackgroundCaspase-11 cleaves gasdermin D for non-canonical inflammasome signalling
Kayagaki, N., Stowe, I. B., Lee, B. L., O’Rourke, K., Anderson, K., Warming, S., Cuellar, T., Haley, B., Roose-Girma, M., Phung, Q. T., et al. (2015) · Nature · doi:10.1038/nature15541 · Cited by 3,686 · cited 1×
“In turn, the mature N-terminal fragment of GSDMD translocates to the inner leaflet of the plasma membrane to form round and pore-like structures of approximately 15 nm in diameter [70] [71] [72] [73] .”
BackgroundImmunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466 · cited 2×
“The IL-1α processing separates NLS from its precursor, which is not linked to secretion or cell death [21]; however, IL-1α is a key danger signal that induces inflammation on release from necrotic cells [42].”
BackgroundApproaching the Asymptote? Evolution and Revolution in Immunology
Janeway, C. A. (1989) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1989.054.01.003 · Cited by 3,252
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202
Activation and regulation of the inflammasomes
Latz, E., Xiao, T. S., & Stutz, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3452 · Cited by 2,884
Endoplasmic reticulum stress and the inflammatory basis of metabolic disease
Hotamisligil, G. S. (2010) · Cell · doi:10.1016/j.cell.2010.02.034 · Cited by 2,802
Pore-forming activity and structural autoinhibition of the gasdermin family
Ding, J., Wang, K., Liu, W., She, Y., Sun, Q., Shi, J., Sun, H., Wang, D.-C., & Shao, F. (2016) · Nature · doi:10.1038/nature18590 · Cited by 2,771
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708 · cited 1×
“NLRP3 inflammasomes have also been reported to be involved in low-grade subclinical inflammation induced by chronic exposure to high levels of free fatty acids and glucose, leading to increased apoptosis and impaired insulin secretion of β-cells in obese type 2 diabetes mellitus (T2D) patients [102] [103] [104] .”
BackgroundInflammation, metaflammation and immunometabolic disorders
Hotamisligil, G. S. (2017) · Nature · doi:10.1038/nature21363 · Cited by 2,570 · cited 1×
“In addition to several forms of inflammation including classical inflammation, homeostatic inflammation, a distinct nomenclature for low-grade inflammation, such as para-inflammation (an adaptive response against stress or malfunction) and meta-inflammation (metabolically triggered inflammation), has been proposed [17…”
BackgroundGasdermin D is an executor of pyroptosis and required for interleukin-1β secretion
He, W.-T., Wan, H., Hu, L., Chen, P., Wang, X., Huang, Z., Yang, Z.-H., Zhong, C.-Q., & Han, J. (2015) · Cell Research · doi:10.1038/cr.2015.139 · Cited by 2,517
Mechanisms and Functions of Inflammasomes
Lamkanfi, M., & Dixit, V. M. (2014) · Cell · doi:10.1016/j.cell.2014.04.007 · Cited by 2,503
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Inflammatory caspases are innate immune receptors for intracellular LPS
Shi, J., Zhao, Y., Wang, Y., Gao, W., Ding, J., Li, P., Hu, L., & Shao, F. (2014) · Nature · doi:10.1038/nature13683 · Cited by 2,285
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Muñoz-Planillo, R., Kuffa, P., Martínez-Colón, G., Smith, B. L., Rajendiran, T. M., & Núñez, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.05.016 · Cited by 2,147
The interleukin-1 family: back to the future
Garlanda, C., Dinarello, C. A., & Mantovani, A. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.010 · Cited by 1,945 · cited 1×
“Currently, human sequence algorithm technologies suggest that the IL-1 family comprises a total of 11 members with similar or distinct biological effects [32, 33] .”
BackgroundInterleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798 · cited 1×
“During ischemic disease, such as MI or cerebral infarction, or tissue injury, cell death by necrosis takes place and the IL-1α precursor is released in sterile inflammation [208] .”
BackgroundTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,682
The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases
Davis, B. K., Wen, H., & Ting, J. P.-Y. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101405 · Cited by 1,618 · cited 2×
“NLRP3-activating DAMPs have also been reported, i.e., self-derived glucose, β-amyloid, hyaluronan, ATP, cholesterol crystals, monosodium urate (MSU) crystals, calcium pyrophosphate dihydrate (CPPD) crystals, environment-derived alum, asbestos, silica, alloy particles, UV radiation, and skin irritants [56] ; however, t…”
BackgroundCloning, sequence and expression of two distinct human interleukin-1 complementary DNAs
March, C. J., Mosley, B., Larsen, A., Cerretti, D. P., Braedt, G., Price, V., Gillis, S., Henney, C. S., Kronheim, S. R., Grabstein, K., et al. (1985) · Nature · doi:10.1038/315641a0 · Cited by 1,579
Noncanonical Inflammasome Activation by Intracellular LPS Independent of TLR4
Kayagaki, N., Wong, M. T., Stowe, I. B., Ramani, S. R., Gonzalez, L. C., Akashi-Takamura, S., Miyake, K., Zhang, J., Lee, W. P., Muszyński, A., et al. (2013) · Science · doi:10.1126/science.1240248 · Cited by 1,545
Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration
Pétrilli, V, Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402195 · Cited by 1,445 · cited 1×
“Instead, efflux of potassium has been identified as the common activator of most known NLRP3 step 2 signals [57, 58] .”
BackgroundRidker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32247-x · Cited by 1,344
Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330 · cited 2×
“Indeed, islet amyloid polypeptide (IAPP) oligomers activated NLRP3 inflammasomes to induce significant IL-1β production by infiltrating macrophages in an in vivo study [105, 106] .”
BackgroundNEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux
He, Y., Zeng, M. Y., Yang, D., Motro, B., & Núñez, G. (2016) · Nature · doi:10.1038/nature16959 · Cited by 1,295 · cited 1×
“The NLRP3 activation by potassium efflux suggested to lead NLRP3-Nek7 interaction to drive inflammasome activation [59] [60] [61] .”
BackgroundCytoplasmic LPS Activates Caspase-11: Implications in TLR4-Independent Endotoxic Shock
Hagar, J. A., Powell, D. A., Aachoui, Y., Ernst, R. K., & Miao, E. A. (2013) · Science · doi:10.1126/science.1240988 · Cited by 1,259
Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN- γ production
Ghayur, T., Banerjee, S., Hugunin, M., Butler, D., Herzog, L., Carter, A., Quintal, L., Sekut, L., Talanian, R., Paskind, M., et al. (1997) · Nature · doi:10.1038/386619a0 · Cited by 1,203
Activation of Interferon-γ Inducing Factor Mediated by Interleukin-1β Converting Enzyme
Gu, Y., Kuida, K., Tsutsui, H., Ku, G., Hsiao, K., Fleming, M. A., Hayashi, N., Higashino, K., Okamura, H., Nakanishi, K., et al. (1997) · Science · doi:10.1126/science.275.5297.206 · Cited by 1,155
GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death
Sborgi, L., Rühl, S., Mulvihill, E., Pipercevic, J., Heilig, R., Stahlberg, H., Farady, C. J., Müller, D. J., Broz, P., & Hiller, S. (2016) · The EMBO Journal · doi:10.15252/embj.201694696 · Cited by 1,152
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages.
Allavena, P., Sica, A., Solinas, G., Porta, C., & Mantovani, A. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.07.004 · Cited by 1,044
IL-1 is required for tumor invasiveness and angiogenesis
Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C. A., & Apte, R. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437939100 · Cited by 1,023
An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist
Aksentijevich, I., Masters, S. L., Ferguson, P. J., Dancey, P., Frenkel, J., van Royen-Kerkhoff, A., Laxer, R., Tedgård, U., Cowen, E. W., Pham, T.-H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807865 · Cited by 987
Weber, A., Wasiliew, P., & Kracht, M. (2010) · Science Signaling · doi:10.1126/scisignal.3105cm1 · Cited by 962 · cited 1×
“This is followed by c-Jun N-terminal kinase (JNK) and p38 MAP kinase [83] .”
BackgroundInterleukin-18 and IL-18 Binding Protein
Dinarello, C. A., Novick, D., Kim, S., & Kaplanski, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00289 · Cited by 938 · cited 1×
“Considering the pathogenesis of IL-1-related diseases, IL-18 could be involved [133] .”
BackgroundNeonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Regulation of inflammasome signaling
Rathinam, V. A. K., Vanaja, S. K., & Fitzgerald, K. A. (2012) · Nature Immunology · doi:10.1038/ni.2237 · Cited by 927
POTENTIATION OF THE T-LYMPHOCYTE RESPONSE TO MITOGENS
Gery, I., Gershon, R. K., & Waksman, B. H. (1972) · The Journal of Experimental Medicine · doi:10.1084/jem.136.1.128 · Cited by 907
GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes
Aglietti, R. A., Estevez, A., Gupta, A., Ramirez, M. G., Liu, P. S., Kayagaki, N., Ciferri, C., Dixit, V. M., & Dueber, E. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607769113 · Cited by 898
Chen, C.-J., Kono, H., Golenbock, D., Reed, G., Akira, S., & Rock, K. L. (2007) · Nature Medicine · doi:10.1038/nm1603 · Cited by 876 · cited 1×
“The IL-1α precursor triggers IL-1R1 on resident macrophages in necrotic tissues, producing IL-1β as well as chemokines as post-necrotic inflammation [43] .”
BackgroundShakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867
The Sterile Inflammatory Response
Rock, K. L., Latz, E., Ontiveros, F., & Kono, H. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101311 · Cited by 865
Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome
Xu, H., Yang, J., Gao, W., Li, L., Li, P., Zhang, L., Gong, Y.-N., Peng, X., Xi, J. J., Chen, S., et al. (2014) · Nature · doi:10.1038/nature13449 · Cited by 850
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
The interleukin‐1 family: 10 years of discovery 1
Dinarello, C. A. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.15.8001745 · Cited by 783 · cited 1×
“They are also expressed in cellular subepithelial endometrial tissue of the uterus, in the glomeruli, in outer cortical areas of the kidney, and in various specific cell types, including neutrophils, keratinocytes, epithelial and endothelial cells, lymphocytes, smooth muscle cells, and fibroblasts [74, 75] .”
BackgroundInterleukin-18 Binding Protein
Novick, D., Kim, S.-H., Fantuzzi, G., Reznikov, L. L., Dinarello, C. A., & Rubinstein, M. (1999) · Immunity · doi:10.1016/s1074-7613(00)80013-8 · Cited by 779
Shi, H., Wang, Y., Li, X., Zhan, X., Tang, M., Fina, M., Su, L., Pratt, D., Bu, C. H., Hildebrand, S., et al. (2016) · Nature Immunology · doi:10.1038/ni.3333 · Cited by 745
Feldmann, J., Prieur, A.-M., Quartier, P., Berquin, P., Certain, S., Cortis, E., Teillac-Hamel, D., Fischer, A., & Basile, G. D. S. (2002) · The American Journal of Human Genetics · doi:10.1086/341357 · Cited by 743
Nishimoto, N., Hashimoto, J., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Murata, N., van der Heijde, D., & Kishimoto, T. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.068064 · Cited by 727
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro
Dinarello, C. A., & Thompson, R. C. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90142-g · Cited by 724
Dunne, A., & O'Neill, L. A. J. (2003) · Science's STKE · doi:10.1126/stke.2003.171.re3 · Cited by 711
Aksentijevich, I., Nowak, M., Mallah, M., Chae, J. J., Watford, W. T., Hofmann, S. R., Stein, L., Russo, R., Goldsmith, D., Dent, P., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10688 · Cited by 709
Stress, Inflammation, and Defense of Homeostasis
Chovatiya, R., & Medzhitov, R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.030 · Cited by 704 · cited 2×
“PRRs directly or indirectly detect infection and/or noxious chemicals, resulting in inflammation that is coupled with the induction of immune responses and a tissue reparative component [8] .”
BackgroundTNF and MAP kinase signalling pathways
Sabio, G., & Davis, R. J. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.02.009 · Cited by 700
Interleukin-1–Receptor Antagonist in the Muckle–Wells Syndrome
Hawkins, P. N., Lachmann, H. J., & McDermott, M. F. (2003) · New England Journal of Medicine · doi:10.1056/nejm200306193482523 · Cited by 654
Robbins & Cotran Pathologic Basis of Disease
Kumar, V., Abbas, A. K., Aster, J. C., & Perkins, J. A. (2004) · Cited by 615
Micallef, M. J., Ohtsuki, T., Kohno, K., Tanabe, F., Ushio, S., Namba, M., Tanimoto, T., Torigoe, K., Fujii, M., Ikeda, M., et al. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260736 · Cited by 597
Interleukin 1 receptor antagonist. A new member of the interleukin 1 family.
Arend, W. P. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115453 · Cited by 595
Hoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577
The PYRIN-CARD Protein ASC Is an Activating Adaptor for Caspase-1
Srinivasula, S. M., Poyet, J.-L., Razmara, M., Datta, P., Zhang, Z., & Alnemri, E. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200179200 · Cited by 573 · cited 1×
“IL-1β is produced as a 269-AA precursor protein and processed by caspase-1, which is also known as IL-1β-converting enzyme (ICE), activated in inflammasomes, to the C-terminal 153 AA as mature IL-1β [11, 12, 34, 44].”
BackgroundMembranoproliferative Glomerulonephritis — A New Look at an Old Entity
Sethi, S., & Fervenza, F. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1108178 · Cited by 565
Chae, J. J., Wood, G., Masters, S. L., Richard, K., Park, G., Smith, B. J., & Kastner, D. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602081103 · Cited by 554
Hoffman, H. M., Rosengren, S., Boyle, D. L., Cho, J. Y., Nayar, J., Mueller, J. L., Anderson, J. P., Wanderer, A. A., & Firestein, G. S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17401-1 · Cited by 552
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Shoham, N. G., Centola, M., Mansfield, E., Hull, K. M., Wood, G., Wise, C. A., & Kastner, D. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135380100 · Cited by 493
Fisher, C. J., Slotman, G. J., Opal, S. M., Pribble, J. P., Bone, R. C., Emmanuel, G., Ng, D., Bloedow, D. C., & Catalano, M. A. (1994) · Critical Care Medicine · doi:10.1097/00003246-199401000-00008 · Cited by 490
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes
De Benedetti, F., Gattorno, M., Anton, J., Ben-Chetrit, E., Frenkel, J., Hoffman, H. M., Koné-Paut, I., Lachmann, H. J., Ozen, S., Simon, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706314 · Cited by 486
Groß, O., Yazdi, A. S., Thomas, C. J., Masin, M., Heinz, L. X., Guarda, G., Quadroni, M., Drexler, S. K., & Tschopp, J. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.018 · Cited by 460
Schmid-Burgk, J. L., Chauhan, D., Schmidt, T., Ebert, T. S., Reinhardt, J., Endl, E., & Hornung, V. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.c115.700492 · Cited by 456
Interleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
Puren, A. J., Fantuzzi, G., & Dinarello, C. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2256 · Cited by 379
IL‐1 and IL‐1 regulatory pathways in cancer progression and therapy
Mantovani, A., Barajon, I., & Garlanda, C. (2018) · Immunological Reviews · doi:10.1111/imr.12614 · Cited by 376 · cited 1×
“IL-1, by promoting MDSCs and sustaining the immunosuppressive activity of TAMs, contributes to the suppression of effective adaptive anti-tumor immune responses [126] .”
BackgroundTargeting of TAK1 in inflammatory disorders and cancer
Sakurai, H. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.06.007 · Cited by 373
Cogswell, J. P., Godlevski, M. M., Wisely, G. B., Clay, W. C., Leesnitzer, L. M., Ways, J. P., & Gray, J. G. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.2.712 · Cited by 371
Multiple biological activities of human recombinant interleukin 1.
Dinarello, C. A., Cannon, J. G., Mier, J. W., Bernheim, H. A., LoPreste, G., Lynn, D. L., Love, R. N., Webb, A. C., Auron, P. E., & Reuben, R. C. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112495 · Cited by 368
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition
Canna, S. W., Girard, C., Malle, L., de Jesus, A., Romberg, N., Kelsen, J., Surrey, L. F., Russo, P., Sleight, A., Schiffrin, E., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.10.022 · Cited by 366
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller‐Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15318 · Cited by 363
Blockade of TNF-α rapidly inhibits pain responses in the central nervous system
Hess, A., Axmann, R., Rech, J., Finzel, S., Heindl, C., Kreitz, S., Sergeeva, M., Saake, M., Garcia, M., Kollias, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011774108 · Cited by 356
Moran, A., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60023-9 · Cited by 356
Dinarello, C., Arend, W., Sims, J., Smith, D., Blumberg, H., O'Neill, L., Goldbach-Mansky, R., Pizarro, T., Hoffman, H., Bufler, P., et al. (2010) · Nature Immunology · doi:10.1038/ni1110-973 · Cited by 351
Rapid responses to anakinra in patients with refractory adult‐onset Still's disease
Fitzgerald, A. A., LeClercq, S. A., Yan, A., Homik, J. E., & Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21061 · Cited by 350
The precursor form of IL-1α is an intracrine proinflammatory activator of transcription
Werman, A., Werman-Venkert, R., White, R., Lee, J.-K., Werman, B., Krelin, Y., Voronov, E., Dinarello, C. A., & Apte, R. N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308705101 · Cited by 346
Anakinra for Rheumatoid Arthritis: A Systematic Review
MERTENS, M., & SINGH, J. A. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090074 · Cited by 344
Böni-Schnetzler, M., Boller, S., Debray, S., Bouzakri, K., Meier, D. T., Prazak, R., Kerr-Conte, J., Pattou, F., Ehses, J. A., Schuit, F. C., et al. (2009) · Endocrinology · doi:10.1210/en.2009-0543 · Cited by 339
Interleukin 1: the first interleukin
di Giovine, F. S., & Duff, G. W. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90005-t · Cited by 338
Cohen, I., Rider, P., Carmi, Y., Braiman, A., Dotan, S., White, M. R., Voronov, E., Martin, M. U., Dinarello, C. A., & Apte, R. N. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915018107 · Cited by 329
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
Everett, B. M., Donath, M. Y., Pradhan, A. D., Thuren, T., Pais, P., Nicolau, J. C., Glynn, R. J., Libby, P., & Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.002 · Cited by 329
Inflammasome-independent regulation of IL-1-family cytokines
Netea, M. G., van de Veerdonk, F. L., van der Meer, J. W. M., Dinarello, C. A., & Joosten, L. A. B. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112306 · Cited by 326 · cited 1×
“The IL-1β precursor is also processed by other serine proteases [45] .”
BackgroundArend, W. P., Joslin, F. G., & Massoni, R. J. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.134.6.3868 · Cited by 322
Mizutani, H., Schechter, N., Lazarus, G., Black, R. A., & Kupper, T. S. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.4.821 · Cited by 317
Caspase‐4 mediates non‐canonical activation of the NLRP3 inflammasome in human myeloid cells
Schmid‐Burgk, J. L., Gaidt, M. M., Schmidt, T., Ebert, T. S., Bartok, E., & Hornung, V. (2015) · European Journal of Immunology · doi:10.1002/eji.201545523 · Cited by 315
Mechanisms of interleukin-1β release
Eder, C. (2009) · Immunobiology · doi:10.1016/j.imbio.2008.11.007 · Cited by 307
Targeting inflammasome/IL-1 pathways for cancer immunotherapy
Guo, B., Fu, S., Zhang, J., Liu, B., & Li, Z. (2016) · Scientific Reports · doi:10.1038/srep36107 · Cited by 302 · cited 2×
“IL-1 is capable of inducing the recruitment of TAMs and MDSCs, which promote tumor development in breast cancer [31] .”
BackgroundEndotoxin-induced serum factor that stimulates gamma interferon production
Nakamura, K., Okamura, H., Wada, M., Nagata, K., & Tamura, T. (1989) · Infection and Immunity · doi:10.1128/iai.57.2.590-595.1989 · Cited by 299
Sugawara, S., Uehara, A., Nochi, T., Yamaguchi, T., Ueda, H., Sugiyama, A., Hanzawa, K., Kumagai, K., Okamura, H., & Takada, H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6568 · Cited by 297
Flores, J., Noël, A., Foveau, B., Lynham, J., Lecrux, C., & LeBlanc, A. C. (2018) · Nature Communications · doi:10.1038/s41467-018-06449-x · Cited by 287
S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1β
Weichand, B., Popp, R., Dziumbla, S., Mora, J., Strack, E., Elwakeel, E., Frank, A.-C., Scholich, K., Pierre, S., Syed, S. N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160392 · Cited by 267
Ballak, D. B., Stienstra, R., Tack, C. J., Dinarello, C. A., & van Diepen, J. A. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.005 · Cited by 255
Gattorno, M., Tassi, S., Carta, S., Delfino, L., Ferlito, F., Pelagatti, M. A., D'Osualdo, A., Buoncompagni, A., Alpigiani, M. G., Alessio, M., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22842 · Cited by 247
Cohen, S. B., Proudman, S., Kivitz, A. J., Burch, F. X., Donohue, J. P., Burstein, D., Sun, Y.-N., Banfield, C., Vincent, M. S., Ni, L., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3430 · Cited by 246
Obesity-associated NLRC4 inflammasome activation drives breast cancer progression
Kolb, R., Phan, L., Borcherding, N., Liu, Y., Yuan, F., Janowski, A. M., Xie, Q., Markan, K. R., Li, W., Potthoff, M. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms13007 · Cited by 239 · cited 1×
“A recent report showed that IL-1β orchestrates tumor-promoting inflammation in patients with high-risk HER2-negative breast cancer who would benefit from IL-1-blocking therapeutics with anakinra (described later on).”
BackgroundDifferences in signaling pathways by IL-1β and IL-18
Lee, J.-K., Kim, S.-H., Lewis, E. C., Azam, T., Reznikov, L. L., & Dinarello, C. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402800101 · Cited by 237 · cited 1×
“Although IL-1β is biologically active within the pg/mL range, IL-18 requires 10–20 ng/mL and sometimes higher levels for in vitro activation [135, 136].”
BackgroundThe NLRP3 inflammasome in kidney disease and autoimmunity
Hutton, H. L., Ooi, J. D., Holdsworth, S. R., & Kitching, A. R. (2016) · Nephrology · doi:10.1111/nep.12785 · Cited by 234
Goldbach‐Mansky, R., Shroff, S. D., Wilson, M., Snyder, C., Plehn, S., Barham, B., Pham, T., Pucino, F., Wesley, R. A., Papadopoulos, J. H., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23620 · Cited by 229
The interleukin-1 receptor family
Boraschi, D., & Tagliabue, A. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.023 · Cited by 227
Granzyme A is an interleukin 1 beta-converting enzyme.
Irmler, M., Hertig, S., MacDonald, H. R., Sadoul, R., Becherer, J. D., Proudfoot, A., Solari, R., & Tschopp, J. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.5.1917 · Cited by 227
Brenner, M., Ruzicka, T., Plewig, G., Thomas, P., & Herzer, P. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09404.x · Cited by 225
Westwell-Roper, C. Y., Ehses, J. A., & Verchere, C. B. (2014) · Diabetes · doi:10.2337/db13-0863 · Cited by 224
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
Haibel, H., Rudwaleit, M., Listing, J., & Sieper, J. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.023176 · Cited by 222
Kim, B., Lee, Y., Kim, E., Kwak, A., Ryoo, S., Bae, S. H., Azam, T., Kim, S., & Dinarello, C. A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00391 · Cited by 218
Processing of precursor interleukin 1 beta and inflammatory disease.
Hazuda, D. J., Strickler, J., Kueppers, F., Simon, P. L., & Young, P. R. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39328-7 · Cited by 217
Hong, D. S., Hui, D., Bruera, E., Janku, F., Naing, A., Falchook, G. S., Piha-Paul, S., Wheler, J. J., Fu, S., Tsimberidou, A. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70155-x · Cited by 199
Rajasekaran, S., Kruse, K., Kovey, K., Davis, A. T., Hassan, N. E., Ndika, A. N., Zuiderveen, S., & Birmingham, J. (2014) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000000078 · Cited by 198
Borghini, S., Tassi, S., Chiesa, S., Caroli, F., Carta, S., Caorsi, R., Fiore, M., Delfino, L., Lasigliè, D., Ferraris, C., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30170 · Cited by 192
Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever: A Randomized Trial
Hashkes, P. J., Spalding, S. J., Giannini, E. H., Huang, B., Johnson, A., Park, G., Barron, K. S., Weisman, M. H., Pashinian, N., Reiff, A. O., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-8-201210160-00003 · Cited by 188
Identification of a specific interleukin 1 inhibitor in the urine of febrile patients.
Liao, Z., Grimshaw, R. S., & Rosenstreich, D. L. (1984) · The Journal of experimental medicine · doi:10.1084/jem.159.1.126 · Cited by 186
Sloan-Lancaster, J., Abu-Raddad, E., Polzer, J., Miller, J. W., Scherer, J. C., De Gaetano, A., Berg, J. K., & Landschulz, W. H. (2013) · Diabetes Care · doi:10.2337/dc12-1835 · Cited by 184
It's time to redefine inflammation
Antonelli, M., & Kushner, I. (2017) · The FASEB Journal · doi:10.1096/fj.201601326r · Cited by 182
Croston, G. E., Cao, Z., & Goeddel, D. V. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16514 · Cited by 180
Frenkel, J., Rijkers, G. T., Mandey, S. H. L., Buurman, S. W. M., Houten, S. M., Wanders, R. J. A., Waterham, H. R., & Kuis, W. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10550 · Cited by 171
Chen, L., Huang, C., Li, Y., Deng, W., Mao, L., Wu, L., Zhang, W., Zhang, L., & Sun, Z. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2720-9 · Cited by 168
Morel, J. C. M., Park, C. C., Woods, J. M., & Koch, A. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103574200 · Cited by 166
Crystallographic refinement of interleukin 1 beta at 2.0 A resolution.
Priestle, J. P., Schär, H. P., & Grütter, M. G. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.9667 · Cited by 165
Wu, T.-C., Xu, K., Martinek, J., Young, R. R., Banchereau, R., George, J., Turner, J., Kim, K. I., Zurawski, S., Wang, X., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0413 · Cited by 165
Beneficial response to interleukin 1 receptor antagonist in traps
Simon, A., Bodar, E. J., van der Hilst, J. C. H., van der Meer, J. W. M., Fiselier, T. J. W., Cuppen, M. P. J. M., & Drenth, J. P. H. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.039 · Cited by 164
Hickish, T., Andre, T., Wyrwicz, L., Saunders, M., Sarosiek, T., Kocsis, J., Nemecek, R., Rogowski, W., Lesniewski-Kmak, K., Petruzelka, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30006-2 · Cited by 164
Pantschenko, A., Pushkar, I., Anderson, K., Wang, Y., Miller, L., Kurtzman, S., Barrows, G., & Kreutzer, D. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.2.269 · Cited by 162
PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and Treatment
Cugno, M., Borghi, A., & Marzano, A. V. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0265-1 · Cited by 162
IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus
Peiró, C., Lorenzo, Ó., Carraro, R., & Sánchez‐Ferrer, C. F. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00363 · Cited by 162
Abbate, A., Kontos, M. C., Abouzaki, N. A., Melchior, R. D., Thomas, C., Van Tassell, B. W., Oddi, C., Carbone, S., Trankle, C. R., Roberts, C. S., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.11.003 · Cited by 160
Rather, L. J. (1971) · Europe PMC (PubMed Central) · Cited by 159
Natural killer cells in human autoimmune diseases
Schleinitz, N., Vély, F., Harlé, J., & Vivier, E. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03360.x · Cited by 158
A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases
Ramos‐Casals, M., Brito‐Zerón, P., Muñoz, S., & Soto, M.-J. (2008) · Medicine · doi:10.1097/md.0b013e318190f170 · Cited by 152
Structure of interleukin 1 .alpha. at 2.7-.ANG. resolution
Graves, B. J., Hatada, M. H., Hendrickson, W. A., Miller, J. K., Madison, V. S., & Satow, Y. (1990) · Biochemistry · doi:10.1021/bi00463a009 · Cited by 152
Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond
Aday, A. W., & Ridker, P. M. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00062 · Cited by 146
Negative regulation of cytokine signaling influences inflammation
Yoshimura, A., Mori, H., Ohishi, M., Aki, D., & Hanada, T. (2003) · Current Opinion in Immunology · doi:10.1016/j.coi.2003.09.004 · Cited by 144
Church, L. D., & McDermott, M. (2009) · PubMed · Cited by 135
Takács, L., Kovacs, E. J., Smith, M. R., Young, H. A., & Durum, S. K. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.9.3081 · Cited by 133
Kanni, T., Argyropoulou, M., Spyridopoulos, T. N., Pistiki, A. C., Stecher, M., Dinarello, C. A., Simard, J. J. L., & Giamarellos‐Bourboulis, E. J. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.10.030 · Cited by 127
An Expanding Role for Interleukin-1 Blockade from Gout to Cancer
Dinarello, C. A. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00232 · Cited by 120
Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency
Galeotti, C., Meinzer, U., Quartier, P., et al. (2012) · Lara D. Veeken · doi:10.1093/rheumatology/kes097 · Cited by 119
Cantini, F., Niccoli, L., & Goletti, D. (2014) · Journal of Rheumatology Supplement · doi:10.3899/jrheum.140103 · Cited by 116
Nakamura, S., Otani, T., Ijiri, Y., Motoda, R., Kurimoto, M., & Orita, K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.6.3330 · Cited by 113
Nakanishi, A., Kaneko, N., Takeda, H., Sawasaki, T., Morikawa, S., Zhou, W., Kurata, M., Yamamoto, T., Akbar, S. M. F., Zako, T., et al. (2018) · Inflammation and Regeneration · doi:10.1186/s41232-018-0085-6 · Cited by 110
Self-citationGattorno, M., Obici, L. P., Cattalini, M., Tormey, V. J., Abrams, K. B., Davis, N., Speziale, A., Bhansali, S. G., Martini, A., & Lachmann, H. J. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-209031 · Cited by 108
Calverley, P. M. A., Sethi, S., Dawson, M., Ward, C. K., Finch, D. K., Penney, M., Newbold, P., & van der Merwe, R. (2017) · Respiratory Research · doi:10.1186/s12931-017-0633-7 · Cited by 108
Prantner, D., Darville, T. L., Sikes, J. D., Andrews, C. W., Brade, H., Rank, R. G., & Nagarajan, U. M. (2009) · Infection and Immunity · doi:10.1128/iai.00883-09 · Cited by 107
IL-1 Strikingly Enhances Antigen-Driven CD4 and CD8 T-Cell ResponsesPreprint
Ben-Sasson, S. Z., Wang, K., Cohen, J. I., & Paul, W. E. (2013) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2013.78.021246 · Cited by 106
Krause, K., Tsianakas, A., Wagner, N., Fischer, J., Weller, K., Metz, M., Church, M. K., & Maurer, M. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.041 · Cited by 106
Mason, D. R., Beck, P. L., & Muruve, D. A. (2012) · Journal of Innate Immunity · doi:10.1159/000334247 · Cited by 105
Isambert, N., Hervieu, A., Rébé, C., Hennequin, A., Borg, C., Zanetta, S., Chevriaux, A., Richard, C., Dérangère, V., Limagne, E., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1474319 · Cited by 101
BAX/BAK-Induced Apoptosis Results in Caspase-8-Dependent IL-1β Maturation in Macrophages
Chauhan, D., Bartok, E., Gaidt, M. M., Bock, F. J., Herrmann, J., Seeger, J. M., Broz, P., Beckmann, R., Kashkar, H., Tait, S. W. G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.087 · Cited by 100
Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease
Bilginer, Y., Ayaz, N. A., & Özen, S. (2009) · Clinical Rheumatology · doi:10.1007/s10067-009-1279-8 · Cited by 95
Owyang, A. M., Maedler, K., Gross, L., Yin, J., Esposito, L., Shu, L., Jadhav, J., Domsgen, E., Bergemann, J., Lee, S., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1124 · Cited by 95
IL-1 Receptor Type 2 Suppresses Collagen-Induced Arthritis by Inhibiting IL-1 Signal on Macrophages
Shimizu, K., Nakajima, A., Sudo, K., Liu, Y., Mizoroki, A., Ikarashi, T., Horai, R., Kakuta, S., Watanabe, T., & Iwakura, Y. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402155 · Cited by 93
Bellora, F., Castriconi, R., Doni, A., Cantoni, C., Moretta, L., Mantovani, A., Moretta, A., & Bottino, C. (2012) · European Journal of Immunology · doi:10.1002/eji.201142173 · Cited by 92
Martin, M. U., Böl, G., Eriksson, A., Resch, K., & Brigelius‐Flohé, R. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240717 · Cited by 91
for the “Working Group” of Systemic Autoinflammatory Diseases of SIR (Italian Society of Rheumatology), Sota, J., Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., Cattalini, M., Manna, R., Cimaz, R., et al. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4119-x · Cited by 90
Abbate, A., Tassell, B. W. V., & Biondi‐Zoccai, G. (2012) · BioDrugs · doi:10.1007/bf03261881 · Cited by 84
McKie, E., Reid, J. L., Mistry, P. C., DeWall, S. L., Abberley, L., Ambery, P., & Extremera, B. G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150018 · Cited by 80
Dubois, E. A., Rißmann, R., & Cohen, A. F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03958.x · Cited by 79
Schenk, M., Fabri, M., Krutzik, S. R., Lee, D. J., Vu, D. M., Sieling, P. A., Montoya, D. J., Liu, P. T., & Modlin, R. L. (2013) · Immunology · doi:10.1111/imm.12167 · Cited by 78
Genetic and Molecular Basis of Inflammasome-mediated Disease
Hoffman, H. M., & Brydges, S. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.135491 · Cited by 78
Deficiency of Interleukin‐1 Receptor Antagonist Responsive to Anakinra
Schnellbacher, C., Ciocca, G., Menendez, R., Aksentijevich, I. A., Goldbach‐Mansky, R. T., Duarte, A. M., & Rivas‐Chacon, R. (2012) · Pediatric Dermatology · doi:10.1111/j.1525-1470.2012.01725.x · Cited by 76
Brikos, C., Wait, R., Begum, S., O'Neill, L. A. J., & Saklatvala, J. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600455-mcp200 · Cited by 73
Effectiveness and Safety of Anakinra for Management of Refractory Pericarditis
Jain, S., Thongprayoon, C., Espinosa, R. E., Hayes, S. N., Klarich, K. W., Cooper, L. T., Moder, K. G., Anavekar, N. S., Oh, J. K., & Matteson, E. L. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.07.047 · Cited by 72
Martin, P., Palmer, G., Vigne, S., Lamacchia, C., Rodriguez, E., Talabot‐Ayer, D., Rose‐John, S., Chalaris, A., & Gabay, C. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0113035 · Cited by 70
Matsuo, Y., Sawai, H., Ma, J., Xu, D., Ochi, N., Yasuda, A., Takahashi, H., Funahashi, H., & Takeyama, H. (2009) · Journal of Surgical Oncology · doi:10.1002/jso.21245 · Cited by 69
Jung, N., Hellmann, M., Hoheisel, R., Lehmann, C., Haase, I., Perniok, A., Hallek, M. J., & RUBBERT, A. (2010) · Clinical Rheumatology · doi:10.1007/s10067-010-1504-5 · Cited by 66
Anti-Interleukin-1 Therapy in the Management of Gout
Schlesinger, N. (2014) · Current Rheumatology Reports · doi:10.1007/s11926-013-0398-z · Cited by 65
Expression and alternative processing of IL‐18 inhuman neutrophils
Robertson, S. E., Young, J. D., Kitson, S., Pitt, A., Evans, J., Roes, J., Karaoglu, D., Santora, L., Ghayur, T., Liew, F. Y., et al. (2006) · European Journal of Immunology · doi:10.1002/eji.200535402 · Cited by 61
Feist, E., Quartier, P., Fautrel, B., Schneider, R., Sfriso, P., Efthimiou, P., Cantarini, L., Lheritier, K., Leon, K., Karyekar, C. S., et al. (2018) · PubMed · Cited by 60
Yang, X., Downey, J. M., Cohen, M. V., Housley, N. A., Alvarez, D. F., & Audia, J. P. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417702890 · Cited by 56
Guan, Y., Zhang, R., Peng, Z., Dong, D., Wei, G., & Wang, Y. (2017) · Journal of bone oncology · doi:10.1016/j.jbo.2017.10.002 · Cited by 54
Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis
Gonçalves, N. P., Vieira, P., & Saraiva, M. J. (2014) · Amyloid · doi:10.3109/13506129.2014.927759 · Cited by 52
The significant role of telomerase activity in human brain tumors
Nakatani, K., Yoshimi, N., Mori, H., Yoshimura, S.-I., Sakai, H., Shinoda, J., & Sakai, N. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970801)80:3<421::aid-cncr10>3.0.co;2-z · Cited by 50
Matsuo, Y., Sawai, H., Ochi, N., Yasuda, A., Takahashi, H., Funahashi, H., Takeyama, H., & Guha, S. (2008) · Journal of Surgical Research · doi:10.1016/j.jss.2008.04.040 · Cited by 43
Autoinflammation: translating mechanism to therapy
Doherty, T. A., Brydges, S. D., & Hoffman, H. M. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.1110616 · Cited by 41
Morikawa, S., Kaneko, N., Okumura, C., Taguchi, H., Kurata, M., Yamamoto, T., Osawa, H., Nakanishi, A., Zako, T., & Masumoto, J. (2018) · International Journal of Immunopathology and Pharmacology · doi:10.1177/2058738418788749 · Cited by 38
Self-citationCardiel, M. H., Tak, P. P., Bensen, W., Burch, F. X., Forejtová, Š., Badurski, J. E., Kakkar, T., Bevirt, T., Ni, L., McCroskery, E., et al. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3163 · Cited by 37
IAPP boosts islet macrophage IL-1 in type 2 diabetes
Mandrup-Poulsen, T. R. (2010) · Nature Immunology · doi:10.1038/ni1010-881 · Cited by 36
Carter, K. W., Hung, J., Powell, B. L., Wiltshire, S., Foo, B. T. X., Leow, Y. C., McQuillan, B., Jennens, M., McCaskie, P. A., Thompson, P. L., et al. (2008) · Human Genetics · doi:10.1007/s00439-008-0540-6 · Cited by 35
Mantovani, A. (2007) · Nature · doi:10.1038/448547a · Cited by 35
Homeostatic inflammation in innate immunity
Miyake, K., & Kaisho, T. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.08.003 · Cited by 32
Revolutionary Change in Rheumatoid Arthritis Managementwith Biological Therapy
Takeuchi, T. (2011) · The Keio Journal of Medicine · doi:10.2302/kjm.60.75 · Cited by 23
Kimura, H. J., Inukai, Y., Takii, T., Furutani, Y., Shibata, Y., Hayashi, H., Sakurada, S., Okamoto, T., Inoue, J., Oomoto, Y., et al. (1998) · Cytokine · doi:10.1006/cyto.1998.0369 · Cited by 22
Roerink, M. E., Groen, R. J. M., Franssen, G. M., de Weem, B. L.-V., Boerman, O. C., & van der Meer, J. W. M. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0149-7 · Cited by 20
Kovalchin, J., King, B. M., Masci, A., Hopkins, E., Fry, J. W., Hou, J., Li, C., Tenneson, K., Weber, S., Wolfe, G. W., et al. (2017) · Eye & Contact Lens Science & Clinical Practice · doi:10.1097/icl.0000000000000414 · Cited by 20
Structure and function of interleukin-1, based on crystallographic and modeling studies
Veerapandian, B. (1992) · Biophysical Journal · doi:10.1016/s0006-3495(92)81796-4 · Cited by 19
Bihorel, S., Fiedler‐Kelly, J., Ludwig, E. A., Sloan‐Lancaster, J., & Raddad, E. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9623-6 · Cited by 19
Homeostatic inflammation, an emerging concept
Ogawa, Y. (2010) · Endocrine Journal · doi:10.1507/endocrj.edt10-08 · Cited by 6
Cited by
Acute Pancreatitis: Diagnosis and Treatment
Szatmary, P., Grammatikopoulos, T., Cai, W., Huang, W., Mukherjee, R., Halloran, C., Beyer, G., & Sutton, R. (2022) · Drugs · doi:10.1007/s40265-022-01766-4 · Cited by 615
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress
Dludla, P. V., Mabhida, S. E., Ziqubu, K., Nkambule, B. B., Mazibuko-Mbeje, S. E., Hanser, S., Basson, A. K., Pheiffer, C., & Kengne, A. P. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i3.130 · Cited by 344
Cellular infiltration in traumatic brain injury
Alam, A., Thelin, E. P., Tajsic, T., Khan, D. Z., Khellaf, A., Patani, R., & Helmy, A. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02005-x · Cited by 297
Pro-Inflammatory and Anti-Inflammatory Interleukins in Infectious Diseases: A Comprehensive Review
Al-Qahtani, A. A., Alhamlan, F. S., & Al-Qahtani, A. A. (2024) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed9010013 · Cited by 291
Metadata
- Authors
- Kaneko, N., Kurata, M., Yamamoto, T., Morikawa, S., & Masumoto, J.
- Venue
- Inflammation and Regeneration
- Published
- 2019-06-06
- Volume
- 39
- Issue
- 1
- Pages
- 12-12
- ISSN
- 1346-8022 (ISSN-L)
- 1880-8190
- OpenAlex
- W2948410175
- Cited by
- 617
- References
- 200
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.